Kitayama Mitchell W sold (to issuer) $315K of ASTH

Kitayama Mitchell W sold (to issuer) 8,500 shares of Astrana Health, Inc. (ASTH) at $37.09 ($0.32M total) on 2026-08-31.

Original reporting
SEC EDGAR · Kitayama Mitchell W
Published Sep 2, 2026, 12:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 1:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ASTH
Neutral
medium confidence
Mentioned
$ASTH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ASTHNeutralLow
01

Why it matters

The disclosed sale is the first public report of this transaction, offering fresh data for investors.

02

Market read

Provides a primary source update on insider ownership, useful for short‑term monitoring.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 4/10Novelty 4/10Timing: filed after market close on 2026-09-01

Background

Form 4 filings disclose insider transactions; directors' sales are monitored for signals.

Company-level read

Ticker impact

$ASTHNeutralMedium confidence
Context

Director Kitayama Mitchell sold 8,500 shares for $315,265, reducing his stake to 24,337 shares.

Expected impact

Minor downward pressure on ASTH price in the short term.

Evidence & confidence

Sale size is small relative to market cap and typical trading volume; impact likely limited.

Market effects

No significant sector impact; insider sale is company‑specific.

Limited to investors tracking ASTH.

None

Counterpoint

The sale could be unrelated to fundamentals and merely portfolio rebalancing.

Key entities

  • Astrana Health, Inc.

    Biopharma company listed on NASDAQ under ticker ASTH.

  • Kitayama Mitchell W

    Director of Astrana Health who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ASTHHighAI 8/10

Astrana Health Earnings Call Highlights Growth and Deleveraging

Astrana Health (ASTH) reported Q3 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). The company highlighted organic growth, debt reduction, and favorable Medicare trends. Management maintained full-year guidance, expecting revenue of $3.9B-$4B and adjusted EBITDA of $261M-$274M. Challenges include Medicaid pressure and seasonality.

$ASTHMed

Astrana Health 3Q 2026: Revenue $1.02B, EPS $0.26 — 10-Q Summary

Astrana Health reported 3Q 2026 revenue of $1.02B, up 7% YoY, and net income of $13.0M, compared to $373K last year. Growth was driven by 9% increase in capitation revenue. Care Partners saw 8% revenue growth and 94% operating income rise, while Care Delivery revenue increased 5% but operating loss widened. Care Enablement revenue rose 5% with 4% higher operating income. Astrana managed 29 IPAs and 1.5M patients as of September 30, 2026.

$ASTHMed

Astrana Health Inc (ASTH) (Q3 2026) Earnings Call Highlights: Record Revenue and EBITDA

Astrana Health Inc (ASTH) reported Q3 2026 earnings, highlighting record revenue and EBITDA growth. CEO Brandon Sim discussed Medicaid membership attrition, Medicare Advantage dynamics, and care enablement business momentum. The company expects mid-teens EBITDA growth despite Medicaid headwinds. A cybersecurity incident is under investigation, and a new 'premiums at risk' disclosure was introduced for ACO business transparency.

$ASTHHighAI 8/10

Astrana Health (ASTH) Q3 2026 Earnings Call Transcript

Astrana Health (ASTH) reported Q3 2026 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). Membership grew to 1.5M, with Medicare Advantage increasing organically. The company completed acquisitions and partnerships, expanding its presence. Medical cost trends were slightly better than expected, with Texas operations performing ahead of plan. Free cash flow reached $105M, and net leverage was reduced to 2.2x.

$ASTHMed

Astrana Health Q3 Earnings Call Highlights

Astrana Health reported 1.5 million members under management, with Medicare Advantage growth offsetting Medicaid attrition. The company expects Medicaid membership to decline 10-15% in 2027, impacting adjusted EBITDA. Medical cost trends were slightly better than expected, with Medicare Advantage margins stable. Astrana plans 82% of capitation revenue from full-risk arrangements by 2026 and completed acquisitions and partnerships.